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Abstract
Absolute tumor DNA copy numbers can currently be achieved only on a single gene basis by using
fluorescence in situ hybridization (FISH). We present GeneCount, a method for genome-wide
calculation of absolute copy numbers from clinical array comparative genomic hybridization data.
The tumor cell fraction is reliably estimated in the model. Data consistent with FISH results are
achieved. We demonstrate significant improvements over existing methods for exploring gene
dosages and intratumor copy number heterogeneity in cancers.
Background
Array comparative genomic hybridization (aCGH) is widely
used for genome-wide mapping of DNA copy number
changes in malignant cells [1,2]. Genetic gains and losses
impact gene expression levels, and thereby promote tumor
growth and progression [3-5]. Numerous clinical studies have
been performed to find tumor characteristics and to classify
patients with respect to their prognosis based on the copy
number changes [6,7]. The usefulness of the aCGH data is
limited, however, because only relative and not absolute copy
numbers are achieved, making the interpretation of the data
and comparisons across experiments difficult. Absolute DNA
copy numbers can be obtained only on a single gene basis by
the use of fluorescence in situ hybridization (FISH). Develop-
ment of genome-wide methods for this purpose would enable
generation of universal gene copy number databases of indi-
vidual diseases that could be utilized more widely, as is the
goal of several public repositories like the Mitelman Database
of Chromosome Aberrations in Cancer [8].
The relative values achieved in aCGH experiments are influ-
enced by the total DNA content (ploidy) of the tumor cells, the
proportion of normal cells in the sample, and the experimen-
tal bias, in addition to the DNA copy numbers. The values are
presented as intensity ratios between tumor and normal DNA
[2]. The data are normalized so that the ratio of 1.0 is the
baseline for the analysis, and corresponds to two DNA copies
in near diploid (2n) tumors. The copy number changes are
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statistical methods for ratio smoothing and breakpoint detec-
tion [9-12]. To assign an absolute copy number to each ratio
level identified by the statistical analysis and thereby score
genetic aberrations are, however, challenging. In aneuploid
tumors with gross alterations in the DNA content, the base-
line represents a copy number other than 2, like 3 or 4 in tri-
or tetraploid tumors, or a non-integer value when the DNA
content differs from n, 2n, 3n, ... mn [13]. The presence of
normal cells within the sample and experimental bias reduce
the ratio dynamics. Moreover, in many tumors, several sub-
populations of malignant cells with different genetic charac-
teristics exist, leading to intratumor heterogeneity in the DNA
copy numbers [14-16] and increased complexity in the data.
Unreliable results occur, therefore, when common ratio levels
are used to score gains and losses in tumors with different
ploidy and normal cell content.
The confounding effect caused by normal cells within tumor
samples is recognized as a problem in aCGH analyses and has
been handled by excluding low purity samples [17,18] or cor-
recting the ratio levels based on histological examination of
tumor sections [6]. The latter approach is not satisfactory
because only the proportion of connective tissue surrounding
the tumor parenchyma, and not the infiltrating immune cells,
is precisely quantified. Moreover, the measurements cannot
be performed on exactly the same tissue as used in the aCGH
experiment and may, therefore, not be representative. A
model including the CGH ratios, ploidy, and experimental
bias has been proposed for estimation of absolute DNA copy
numbers in tumor cell lines [19]. To our knowledge, no
method exists that also considers the normal cell content and,
thus, is suited for analyses of clinical tumor samples.
We here present a new model, GeneCount, where the propor-
tion of normal cells is estimated and corrected for and possi-
ble intratumor heterogeneity in DNA copy numbers is
considered. Inputs to our model are the DNA index (DI,
where DI = 1/2·tumor ploidy), tumor cell fraction, experi-
mental bias, and aCGH ratios. Predetermined measures of
tumor ploidy, determined either by flow or image based
cytometry, are needed. The tumor cell fraction can be deter-
mined by, for example, flow cytometry on the same part of the
sample as used in the aCGH experiment. In cases of unknown
normal cell content, the tumor cell fraction is estimated in the
model. The experimental bias is determined from the X-chro-
mosome ratio in aCGH experiments where male and female
DNA is compared. Smoothed ratio levels from any existing
statistical analysis tools for breakpoint detection can be used.
We show that the model enabled automatic and genome-wide
calculation of DNA copy numbers from aCGH data of both
hematopoietic and solid tumors. The feasibility of GeneCount
was demonstrated by analysis of 94 lymphomas, for which
the DNA index and tumor cell fraction had been determined
by use of flow cytometry and an extensive exploration of DNA
copy numbers had been performed by the use of FISH in pre-
vious studies [20-25]. The GeneCount results, both based on
the pre-determined tumor cell fraction and that determined
by the model, were compared with the FISH data of 362 genes
with and without gains and losses, showing 97% consistency
in both cases. In particular, we explored the copy numbers
achieved in the t(14;18) translocated chromosomal region
involving BCL2. We further demonstrated the potential of
GeneCount in analysis of solid tumors without pre-deter-
mined tumor cell fractions by relating the copy number of
selected genes in 93 cervical cancers to gene expression and
treatment outcome. By use of GeneCount we obtained a
higher sensitivity in detecting cervix tumors with copy
number changes than was obtained in analysis based directly
on the ratio levels. Finally, we identified intratumor heteroge-
neity of DNA copy numbers in the lymphomas and cervical
cancers, and showed how this information could be used to
draw conclusions about the evolution of the genetic aberra-
tions in the tumors. GeneCount was implemented in a soft-
ware package to be used downstream of statistical methods
for breakpoint detection, and results based on both the GLAD
and CGH-Explorer packages are presented [9,11]. We supply
our method through the open-source and free web-based
database BioArray Software Environment (BASE) [26].
Results
Basis of GeneCount
Our model utilizes the fact that the normalized aCGH ratio
increases with increasing DNA copy number in a stepwise
manner, where the step size is dependent on the DI, the
tumor cell fraction, and the experimental bias (Figure 1). In
near diploid tumors (DI = 1) without a contribution from nor-
mal cells or affected by experimental bias, an increment of 1
in the copy number increases the ratio by a value of 0.5, lead-
ing to a normalized ratio of 0.5, 1, 1.5, 2, and so on (-1, 0, 0.69,
1 on a log2 scale) for a copy number of 1, 2, 3, and 4, respec-
tively (see Equation 2 in Materials and methods). The corre-
sponding increase in tetraploid tumors (DI = 2) is 0.25,
whereas an increase between 0.25 and 0.5 occurs in tumors
with a DI between 1 and 2. Baseline, at a log2 ratio of 0, corre-
sponds to 2, 3, and 4 DNA copies in near diploid (Figure 1a),
triploid, and tetraploid (Figure 1b) tumors, respectively. For
DIs between 1 and 1.5 or between 1.5 and 2, baseline repre-
sents a copy number between 2 and 3 (Figure 1c) or between
3 and 4. The presence of normal cells within the tumor sam-
ple reduces the increase in aCGH ratio with incremental copy
number (Equation 3), as can be seen when comparing the
ratios of two near diploid lymphomas with different tumor
cell fractions (Figures 1a,d). Using common ratio levels for
scoring gains and losses in tumors like those presented in Fig-
ures 1a-d leads, therefore, to different results with respect to
copy number changes.
A further reduction in the ratio dynamics occurs due to exper-
imental bias (Equation 4). The bias, as represented by theGenome Biology 2008, 9:R86
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ments, where normal DNA from males and females is cohy-
bridized (Figure 1e). Theoretically, the X-chromosome ratio is
0.5 (-1 on a log2 scale), but the experimental bias reduces the
ratio dynamics, leading to a ratio level closer to zero. The
absolute value of the log2-transformed ratio level was used as
a measure of q (Figure 1e). This value differed little among the
slide series used here, ranging from 0.75-0.85 with a mean ±
standard deviation of 0.80 ± 0.04 based on 8 control experi-
ments. A q-value of 0.8 and range of 0.7-0.9 was used in the
GeneCount calculations in the cases of known and unknown
tumor cell fraction, respectively.
To enable automatic calculation of the copy number associ-
ated with each array probe, we implemented GeneCount in a
program to be run on top of statistical analysis packages for
aCGH ratio smoothing and breakpoint detection (Additional
data file 1). A separate algorithm was developed for samples
with unknown tumor cell fraction, where the fraction was
estimated based on two ratio levels and DI (panel B in Addi-
tional data file 1), as described in Materials and methods. One
decimal was included in the calculated DNA copy numbers
when evaluating the results in comparison with FISH data.
Otherwise, the numbers were rounded off to the nearest inte-
ger values.
GeneCount copy numbers in comparison with FISH 
data
We compared the GeneCount results of 94 lymphomas with
previously published FISH data from the same tumors [20-
25]. The FISH probes were located at chromosomal regions
with frequent copy number changes (Figure 1 and Additional
data file 2), and copy numbers within the range of 0-8 had
been measured. The DIs, ranging from 0.95-2.23, and the
tumor cell fractions, ranging from 27% to 98%, were used as
inputs to GeneCount, together with the smoothed aCGH
ratios from the GLAD and CGH-Explorer packages. CGH-
Explorer applied a more extensive ratio smoothing than
GLAD, and this led occasionally to differences in the ratio lev-
els and breakpoint detection between the two programs.
GeneCount with known tumor cell fraction
In most cases, we found an excellent agreement between the
DNA copy number determined by GeneCount and FISH,
Illustration of the stepwise increase in aCGH ratios with increasing DNA copy numberFigu e 1 (see previous  page)
Illustration of the stepwise increase in aCGH ratios with increasing DNA copy number. Frequency histograms (% array probes) of aCGH ratios (left 
panels) and plot of aCGH ratio versus chromosomal location (right panels) are shown for a lymphoma with a DNA index (DI) of (a) 1.02, (b) 1.94, (c) 
1.21, and (d) 1.05, and (e) for normal DNA comparing male and female. The tumor cell fraction, measured by flow cytometry, is indicated for each tumor. 
DNA copy numbers estimated by GeneCount are marked; those in black were consistent with FISH data, whereas those in red have not been subjected 
to FISH measurements in the specific tumors shown. The arrows in the right panels point to the locations of the FISH probes. At a DI close to 1 and 2 
(a,b,d,e) the ratio distribution shows a major peak at a median log2 value of approximately zero, representing the most frequent DNA copy numbers of 2 
and 4, respectively. At a DI of 1.21 (c) the baseline at a log2 ratio of 0 represents a number between 2 and 3 DNA copies. Note the smaller increase in the 
ratios with increasing DNA copy number at a tumor cell fraction of 70% (d) than of 96% (a). In (e), determination of the dynamic factor, q, as the absolute 
value of the X-chromosome log2 ratio level is indicated.
GeneCount calculations with known tumor cell fractionFigure 2
GeneCount calculations with known tumor cell fraction. DNA copy 
number calculated by GeneCount is plotted against the corresponding 
FISH result for 9 genes in 94 lymphomas. The smoothed aCGH ratios 
from (a) GLAD and (b) CGH-explorer, a q-value of 0.8, and a DI and 
tumor cell fraction determined by flow cytometry were inputs to 
GeneCount. Grey and blue columns represent GeneCount results that 
were consistent and inconsistent with the FISH data, respectively, after 
rounding off the GeneCount number to the nearest integer value. 
Frequency distributions are shown for each copy number, containing 1, 25, 
246, 66, 15, 5, 4, and 1 value at a FISH copy number of 0, 1, 2, 3, 4, 5, 6, 
and 8, respectively.
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breakpoint detection (Figure 2). The correlation between the
data sets was considerably better than when the ratio levels
were used in the comparison (Additional data file 3). Based
on GLAD, 350 out of 362 GeneCount values were consistent
with the FISH data (97%), whereas the corresponding
number based on CGH-Explorer was 340 out of 362 (94%)
(Figure 2). The few discrepancies between the GeneCount
and FISH results occurred mainly for two reasons. First,
GLAD and/or CGH-Explorer failed to detect the ratio change
of some of the genes that had a copy number change by FISH
(panel A in Additional data file 4). Second, the ratio level, and
therefore the copy number, was inaccurately determined for
some aberrations involving only a few array probes (panel B
in Additional data file 4). This was primarily the case for aber-
rations with less than three probes, like the homozygote dele-
tion involving two probes that covered RB1 in one of the
tumors (FISH copy number of 0 in Figure 2 and panel B in
Additional data file 4). The discrepancies between the Gene-
Count and FISH data were related, therefore, to the software
used for breakpoint detection and not due to errors in the
GeneCount algorithm.
GeneCount with unknown tumor cell fraction
The tumor cell fraction could be estimated for 55 and 43 out
of 94 lymphomas based on GLAD and CGH-Explorer,
respectively. The remaining tumors lacked aberrations or two
different ratio levels that could be used for the estimation
(Materials and methods). The estimated tumor cell fractions
correlated significantly with those measured by flow cytome-
try (Figure 3). Moreover, the estimates had a coefficient of
variance (CV) of less than 11% (Figure 3), and were therefore
fairly stable. The mean q-value determined in the calculation
differed little across the tumors, ranging from 0.73-0.84
(GLAD) and 0.74-0.82 (CGH-Explorer) (data not shown).
The consistency between the GeneCount and FISH data (Fig-
ure 4) was comparable to when the known tumor cell fraction
was used (Figure 2) and much better than when the ratio lev-
els and FISH data were compared (Additional data file 3).
Based on GLAD, 218 out of 231 DNA copy numbers were in
agreement with the FISH data (94%), whereas the corre-
sponding numbers based on CGH-Explorer were 173 out of
179 (97%) (Figure 4). Most differences between the Gene-
Count and FISH results occurred for the same reasons as
when the known tumor cell fraction was used (Additional
data file 4). Additionally, a discrepancy was seen for some of
the highest copy numbers based on GLAD (Figure 4), due to a
large discrepancy between the estimated and measured
tumor cell fraction in one of the cases (Figure 3a).
DNA copy numbers in translocated chromosomal regions
The relationship between the GeneCount estimates and FISH
data in translocated chromosomal regions was explored by
using BCL2, which is involved in the translocation t(14;18) in
lymphomas, as an example. The aCGH probe covering BCL2
is located telomeric of the breakpoint. The aCGH data and
GeneCount results of BCL2 were therefore not affected by the
translocation. For FISH analysis, we selected a BCL2 probe
covering the breakpoint. The probe signal was split in tumors
with translocation, leading to a signal from both
der(14)t(14;18) and der(18)t(14;18), although BCL2 is located
on the former chromosome. The FISH signal was therefore
higher than the actual BCL2 copy number, and differed from
the GeneCount result in all 38 tumors with translocation (Fig-
ure 5a). After recalculating the FISH copy numbers as
described [22], the consistency in the data was excellent,
except in one case at a corrected FISH value of five copies
(Figure 5b). This discrepancy was due to failure of GLAD and
GeneCount estimations of tumor cell fractionFigure 3
GeneCount estimations of tumor cell fraction. Tumor cell fraction of 
lymphomas estimated by GeneCount is plotted against tumor cell fraction 
measured by flow cytometry. Each point represents mean ± standard 
deviation based on the values achieved for q within the range 0.7-0.9. The 
smoothed aCGH ratios from (a) GLAD and (b) CGH-explorer, the q 
range 0.7-0.8, and a DI determined by flow cytometry were inputs to 
GeneCount. The calculations were based on 55 (a) and 43 (b) tumors for 
which suitable ratio levels for the calculations existed. Correlation 
coefficients and P-values from Pearson product moment correlation 
analyses are indicated.
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BCL2 (panel C in Additional data file 4).
GeneCount analysis of solid tumors
The feasibility of our method for analysis of solid tumors
without information of tumor cell fraction was explored in 99
cervical cancers, for which the DI ranged from 1.00-3.16. The
tumor cell fraction could be estimated for 93 and 89 tumors
based on GLAD and CGH-Explorer, respectively, fulfilling the
requirements for this estimation (Materials and methods).
The tumor cell fractions were poorly correlated with the val-
ues determined by analysis of histological sections (Addi-
tional data file 5). In most cases, the histology result was
higher than the GeneCount estimate, probably because
immune cells infiltrating the tumor parenchyma were not
properly quantified by the histological examination. In a few
cases, however, the histology result was higher, probably
reflecting that different parts of the sample were used in the
aCGH and histology analyses. The tumors for which the
tumor cell fraction could be estimated by GeneCount were
included in the further analyses.
A higher number of genetic aberrations were generally found
in the cervical cancers than in the lymphomas. High level
amplifications with more than 2.5-fold increases in gene
dosage (that is, copy number, N, relative to total DNA content
given by two times the DNA index (N/(2.DI)), were found in
about half of the tumors and most frequently on chromo-
somes 5p and 11q. GeneCount analysis showed copy numbers
within the range of 5-80 in these regions, which were often
surrounded by gains at lower levels.
The GeneCount results were compared with the outcomes of
existing analysis methods, where gains and losses were
scored from the smoothed ratio levels and breakpoints
obtained by GLAD and CGH-Explorer. The log2 transformed
ratio levels of ± 0.2 (that is, approximately two times the ratio
standard deviation (Additional data file 6)) were applied as
cut-off levels for scoring aberrations. We selected genes that
were shown to be affected by gains and losses in previous
studies on a subgroup of the patients [27]. Some of the genes
showed only a small variation in the aCGH ratios, often
within the level of ± 0.2, and only a few tumors with aberra-
tions were identified (Figure 6a and panel A in Additional
data file 7). A higher number of patients with changes in gene
copy numbers and in the corresponding gene dosages were
identified with GeneCount, using the cut-off levels of ± 0.2 for
scoring gene dosage changes (Figure 6b,c and panels B and C
in Additional data file 7). The gene dosage correlated signifi-
cantly with gene expression (Figure 6c and panel C in Addi-
tional data file 7), making the copy number changes
determined by GeneCount plausible.
The copy number changes of MRPS23 have previously been
shown to correlate with survival probability [27]. Survival
analysis based on the GeneCount data of MRPS23 identified
more patients with poor outcome than the corresponding
analysis based on ratio levels (Figure 6d,e). Hence, 15 high
risk patients were identified based on the GeneCount results,
whereas only 5 patients were classified with high risk based
on the ratio levels. Nine of the ten patients that were not iden-
tified based on ratio levels (blue curve in Figure 6d) had ane-
uploid tumors with a DNA index ranging from 1.10-1.92. The
remaining diploid tumor had a relatively low tumor cell frac-
tion of 23%.
GeneCount estimations with unknown tumor cell fractionFigure 4
GeneCount estimations with unknown tumor cell fraction. DNA copy 
number calculated by GeneCount, using a q-value within the range 0.7-0.9, 
a DI determined by flow cytomery, and the tumor cell fraction estimated 
by GeneCount in Figure 3, is plotted against the corresponding FISH result 
for 9 genes in (a) 55 and (b) 43 lymphomas. The smoothed array CGH 
ratio derived from GLAD and CGH-explorer was used in (a) and (b), 
respectively. Grey and blue columns represent GeneCount results that 
were consistent and inconsistent with the FISH data, respectively, after 
rounding off the GeneCount value. Frequency distributions are shown for 
each copy number, containing 1, 19, 134, 56, 11, 5, 4, and 1 value at a FISH 
copy number of 0, 1, 2, 3, 4, 5, 6, and 8, respectively, based on GLAD. The 
corresponding numbers based on CGH Explorer were 1, 15, 98, 48, 7, 5, 
4, and 1.
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Some tumors had genome regions for which the aCGH ratio
was clearly different from that corresponding to an integer
copy number. This probably reflected intratumor heterogene-
ity in the DNA copy numbers, that is, the existence of subpop-
ulations with copy number changes that are not common for
all tumor cells in the sample. The common aberrations can
thus be considered homogeneous. Lymphomas and cervical
cancers with heterogeneous DNA regions had ratio levels that
fell in between, and were significantly different from, those
GeneCount estimations in the t(14;18) translocated region involving BCL2Figure 5
GeneCount estimations in the t(14;18) translocated region involving BCL2. BCL2 copy number estimated by GeneCount, using a q-value of 0.8 and a DI and 
tumor cell fraction determined by flow cytometry, is plotted against the corresponding FISH result in 94 lymphomas. The smoothed array CGH ratios 
derived from GLAD and CGH-explorer were used in the left and right panels, respectively. Grey and blue columns represent GeneCount calculations that 
were consistent and inconsistent with the FISH measurements, respectively, after rounding off the GeneCount value. (a) Uncorrected FISH data are 
plotted; (b) these data were corrected as described in [22]. Frequency distributions are shown for each copy number, containing 1, 38, 33, 13, 5, and 1 
value for a red spot FISH copy number of 1, 2, 3, 4, 5, and 6. The corresponding number of measurements for the corrected FISH data of 1, 2, 3, 4, 5, and 
6 were 1, 69, 14, 4, 2 and 1.
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level reflected the proportion of cells with that aberration
(Equation 1).
Nineteen (20%) lymphomas and 44 (50%) cervical cancers
had one or more heterogeneous DNA regions with copy num-
bers 1&2, 2&3, or 3&4 (Additional data files 8 and 9). Reliable
detection of heterogeneity required tumor cell fractions above
24% (Additional data file 10) and 5 out of 93 cervical cancers
were therefore excluded from this analysis. Lymphoma
L309/89 (Figure 7) had previously been identified as hetero-
geneous by FISH, showing one population with three and
another with four copies of MYC and centromeres 8 and 17
[20]. Moreover, several of the heterogeneous aberrations in
the cervical cancers, such as loss on chromosome 4 and X and
gain on 11q and 17 in C005/01, loss on 6q and gain of 11q in
C006/01, and loss on 4 in C023/01, were similar to those
detected earlier by conventional CGH [14]. The previous
study was, however, based on a different set of biopsies,
which probably explains the lack of consistency for some of
the tumors.
In a few of the heterogeneous tumors, two different ratio lev-
els were identified between one and two copies (Figure 8 and
Additional data file 11). Thus, it appeared that the corre-
sponding aberrations were present in different fractions of
the tumor cell population. Lymphoma L008/92 had two
intermediate ratio levels between one and two copies, corre-
sponding to 70% and 30% of the tumor cells (Figure 8b, blue
and red ratios, respectively), leading to the possible tumor
evolutionary schemes depicted in Figure 8c. As the sum of the
two fractions did not exceed 100%, the heterogeneous aberra-
tions may be found in non-overlapping subpopulations of the
tumor, where the subpopulations have evolved differently
from a predicted common population containing the homog-
enous aberrations (parallel sequence). A serial sequence,
where the populations have evolved in a linear manner from
a common population, was also possible. In C024/01, how-
ever, the heterogeneous ratio levels corresponded to 78% and
44% of the tumor cells, and a serial sequence was the only one
suggested (panel C in Additional data file 11).
Discussion
We have shown that GeneCount is a reliable method for
genome-wide calculation of DNA copy numbers in clinical
tumor samples. Such data are biologically interesting in
themselves but may also lead to improved prediction of
treatment outcome and aid in the identification of novel
tumor suppressors and oncogenes. We applied the method to
lymphomas, for which accurate measures of tumor cell frac-
tion and DNA copy numbers have been obtained by other
techniques that could be compared with the GeneCount
results. We further used the method on cervical cancers, for
which tumor cell fractions representative of the aCGH data
are more difficult to achieve by a separate technique. The
GeneCount analyses in cervical cancersFigure 6
GeneCount analyses in cervical cancers. (a) Frequency histogram (number 
of tumors) of smoothed aCGH ratios (GLAD) for MRPS23 (BAC clone ID 
RP11-19F16). Dotted lines indicate the cut off ratio levels of ± 0.2, 
identifying 5 tumors with genetic gain and 3 tumors with loss. (b) 
Frequency histogram (number of tumors) of MRPS23 copy number 
calculated by GeneCount. The GLAD ratio levels, the DI measured by flow 
cytometry, and the tumor cell fraction estimated by GeneCount were 
used in the calculation. Similar results were achieved based on the CGH-
Explorer ratio levels. (c) Plot of gene expressions against gene dosage; 
that is, the MRPS23 copy number divided by the total DNA content (N/
(2·DI)). Increased gene dosage with more than 15% of the total DNA 
content (log2 transformed gene dosage of at least 0.2) were seen in 15 
tumors (red and blue symbols). Red symbols represent the five tumors 
with gain in (a), whereas blue symbols represent the remaining ten tumors 
with increased gene dosage that were not identified in (a). The correlation 
coefficient and P-value from Pearson product moment correlation analysis 
are indicated. (d) Kaplan Meier analysis based on GeneCount results for 
MRPS23. Plots of the survival probability are shown for 5 patients with 
high gene dosage in (c), who also had gain in (a) (red line), 10 patients with 
high gene dosage in (c) and without gain in (a) (blue line), and 78 patients 
with low gene dosage in (c). (e) Kaplan Meier analysis based on the 
MRPS23 ratio levels. The survival probability of 5 patients with gain in (a) 
(red line) and 88 patients without gain in (a) (black line) is plotted. Only 
five high risk patients were identified in (e), whereas ten more patients 
were identified by GeneCount in (d). P-value in log-rank test is indicated in 
(d,e). Panels (a,b,d) are based on 93 tumors, for which the tumor cell 
fraction could be estimated by GeneCount. Panel (c) is based on 89 of 
these tumors, for which both DNA copy number and gene expression 
were available.
-1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0 1.2
-1.6
-1.2
-0.8
-0.4
0.0
0.4
0.8
1.2
-0.4 -0.3 -0.2 -0.1 0.0 0.1 0.2 0.3 0.4 0.5 0.6
0
10
20
30
40
N
um
be
r 
of
tu
m
or
s
aCGH ratio level (log2)
Gene copy number
Gene dosage (log2)
N
um
be
r 
of
tu
m
or
s
G
en
e 
ex
pr
es
si
on
(lo
g 2
)
r = 0.44
P <0.001 
(a)
(b)
(c)
Follow up time (month)
P
ro
gr
es
si
on
 fr
ee
 s
ur
vi
va
l
(d)
P
ro
gr
e s
si
on
 fr
ee
 s
ur
vi
va
l
(e)
P = 0.001
Low aCGH ratio level (n=88)
High aCGH ratio level (n=5)
P = 0.001
Low gene dosage (n=78)
High gene dosage (n=5)
High gene dosage (n=10)
MRPS23
0 1 2 3 4 5 6 7 8 9 10
0
10
20
30
40
50
60
Follow up time (month)Genome Biology 2008, 9:R86
http://genomebiology.com/2008/9/5/R86 Genome Biology 2008,     Volume 9, Issue 5, Article R86       Lyng et al. R86.9GeneCount model is simple, due to the use of normal cells
with two DNA copies throughout the genome as a reference
sample. Moreover, the estimated copy numbers are restricted
to positive integers, increasing the robustness of the method.
A requirement for achieving the absolute quantification for-
mat is the use of pre-determined tumor ploidies, whereas the
tumor cell fractions, if not known, and experimental bias can
be estimated from the aCGH data.
The experimental bias is mainly caused by signals from
unsuppressed repetitive sequences and nonspecific hybridi-
zation [2]. The bias influences the test and reference sample
equally and independently of the DNA copy number, since it
is generated by sequences distributed throughout the
genome. The bias could, therefore, be summed up in an array
specific factor, q, representing the dynamics of the log-trans-
formed ratios. Mohapatra et al. [19] included the bias as a
constant factor affecting the absolute, rather than the log-
transformed, ratios in their model for pure tumor cells. Our
approach seems justified because the noise (width) of the log-
transformed ratios was independent of the ratios and, there-
fore, of the DNA copy numbers (Additional data file 6). We
allowed for a small variation in q when calculating the tumor
cell fraction to account for minor differences in the bias
across the tumors. This q-value, optimized for each tumor,
was highly similar to the mean q determined from control
experiments, indicating that the bias was stable across exper-
iments. Moreover, the discrepancies between the GeneCount
and FISH results were related to the specific genetic aberra-
tion involved and, therefore, to the breakpoint detection
algorithm, rather than to possible uncertainties in q. Recent
developments in array CGH technology, utilizing oligonucle-
otides rather than bacterial artificial chromosome (BAC)
clones, led to improved ratio dynamics and reduction in the
experimental bias due to less repetitive sequences [28].
Ongoing work in our laboratory shows that by using oligoar-
rays, GeneCount can be applied with a q value close to 1.
Inclusion of the tumor cell fraction is a prerequisite for the
calculation of absolute DNA copy numbers in clinical tumor
samples. The lymphoma data were based on single cell sus-
pensions made from the entire lymph nodes. A tumor cell
fraction representative of the lymph node could, therefore, be
determined with high accuracy by a separate technique like
flow cytometry. In solid tumors such as cervical cancers, the
normal cells consist of stroma, which is highly heterogene-
ously distributed within the tissue, and immune cells, which
infiltrate the tumor parenchyma. A measure of the tumor cell
fraction achieved by, for example, histological examination,
which is based on a part of the sample different from that
used for the aCGH experiment and/or fails to quantify the
proportion of immune cells accurately, is, therefore, not pre-
cise enough for the calculation of DNA copy numbers.
Histology data may, however, be useful for preselecting
tumor enriched samples for the aCGH analysis. Fairly stable
estimates of the tumor cell fraction, consistent with the values
GeneCount identification of DNA copy number heterogeneity within tumorsFigure 7
GeneCount identification of DNA copy number heterogeneity within 
tumors. (a) Frequency histogram (% array probes) of aCGH ratios in a 
heterogeneous lymphoma, including data for the entire genome. (b) 
aCGH ratios are plotted against chromosomal location, showing the 
heterogeneous regions on chromosomes 8, 9, and 17 with a DNA copy 
number of 3&4 in blue. (c) Frequency histogram (% array probes) of 
aCGH ratios for two homogeneous DNA regions with a copy number of 
3&4 (upper panel) and the heterogeneous region depicted in (b) with a 
copy number of 3&4 (lower panel). The ratio distributions of copy number 
3, 4, and 3&4 were significantly different (p < 0.001, ANOVA). DNA copy 
numbers estimated by GeneCount from the DI and tumor cell fractions 
measured by flow cytometry are marked; those in black were consistent 
with FISH experiments, whereas those in red have not been subjected to 
FISH measurements in the specific tumors shown. The arrows in (b) point 
to the locations of the FISH probes. Note that the 3&4 copy number of 
the heterogeneous region has been confirmed with FISH.
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GeneCount. The estimates led to DNA copy numbers in agree-
ment with the FISH data, suggesting that the accuracy of the
tumor cell fractions was sufficient for reliable data analysis.
Selection of appropriate ratio levels for the estimation was
crucial for achieving this accuracy. We required that the
tumors had at least two aberrations with different copy num-
bers and with more than ten array probes each to reduce
errors caused by poorly defined ratio levels and breakpoints.
Moreover, only ratio levels deviating more than 0.15 (log2
scale) from the baseline were selected, implying that tumor
fractions higher than 24% (diploid) and 36% (tetraploid)
were needed when copy numbers were changed to 3 or 5 cop-
ies, respectively (Additional data file 12).
The few discrepancies between the GeneCount and FISH data
were not related to our model, but rather to the ability of the
statistical methods to detect some of the aberrations. Hence,
the consistency between the GeneCount and FISH results was
similar to the reliability of GLAD in detecting breakpoints in
simulated data [9]. The highest accuracy of the GeneCount
results was obtained for well defined aberrant regions con-
taining at least three array probes. In these cases a ratio level
representative of the corresponding copy number was
achieved and the probability of detecting the aberration was
high. The increased uncertainty in the results of narrow aber-
rations implies that they should be confirmed by a separate
technique like FISH. Moreover, to ensure sufficient ratio
dynamics and, therefore, a high probability of breakpoint
detection, a tumor cell fraction higher than a certain value,
which depends on the experimental noise and tumor ploidy,
is needed. With the noise of our experiments (Additional data
file 6), a tumor cell fraction above 23% in diploid, and some-
what higher in hyperdiploid cases, enabled separation of an
aberration with more than three array probes (Additional
data file 13). This fraction also enabled detection of heteroge-
neous DNA copy numbers involving more than ten array
probes (Additional data file 10). In experiments with more
Figure 8
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Evolutionary sequences of subpopulations in heterogeneous tumorsFigure 8
Evolutionary sequences of subpopulations in heterogeneous tumors. (a) 
Frequency histogram (% array probes) of aCGH ratios in a heterogeneous 
lymphoma is shown, including data for the entire genome. (b) The aCGH 
ratios are plotted against chromosomal location. The heterogeneous 
regions on chromosomes 2q, 5p, 7q, 9p, 13q, 20q, and Xp with a DNA 
copy number of 1&2 and on chromosomes 2p, 4q, 6p, 11q, and 18 with a 
DNA copy number of 2&3 are shown in blue and red. The blue and red 
colors represent aberrations that are present in different fractions of the 
tumor cells; 70% and 30%, respectively. The heterogeneous aberrations 
are listed in Additional data file 8 except those with a copy number of 2&3, 
since the lack of 3 DNA copies in this tumor prevented statistical analysis 
to identify 2&3 heterogeneity. (c) Schematic diagram of two possible 
evolutionary sequences for the aberrations, one parallel and one serial 
sequence, are shown. The blue and red circles represent the blue and red 
aberrations in (b). The percentages indicate the fractions of tumor cells 
with the listed aberrations, as calculated by GeneCount, showing that the 
aberrations in blue and red are present in 70% and 30% of the tumor cells, 
respectively.Genome Biology 2008, 9:R86
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tumor cell fractions are required. In comparison, at least 50%
tumor cells is suggested for optimal detection of gains and
losses by conventional CGH [29].
The DNA copy number of genes involved in translocations
cannot be directly assessed by FISH when a probe covering
the breakage region is used, because signals from both the
original chromosomes are detected in the translocated
derivatives. Correction of the probe signal to achieve the true
copy number requires knowledge of the breakpoint and genes
involved in the translocation. Reliable FISH analysis in solid
tumors, where the translocations are not well identified and
may occur throughout the genome [30] is, therefore, particu-
larly challenging. By aCGH, the probe signal is measured
independently of the actual genome organization of the DNA
covered by the probe. Hence, in the case of balanced translo-
cations, a correct result will be obtained even if the probe cov-
ers the breakpoint. If the probe is located at the start or end of
an amplified or deleted region (unbalanced translocation),
the aCGH ratios of the adjacent probes ensure that the correct
copy number is calculated. Our model therefore provides a
novel method for assessment of copy numbers both in bal-
anced and unbalanced translocated regions and without
knowing that the translocation exists.
Current methods for analysis of aCGH data generally score
genetic gains and losses based on ratio levels [31-36]. The
breakpoints in individual tumors can be detected with high
accuracy by use of statistical algorithms like GLAD and CGH-
Explorer. However, the existing downstream analyses, using
common ratio levels for scoring aberrations across tumors,
fail to identify gains and losses in cases of high ploidy and
normal cell content. By the use of GeneCount, the ratio levels
are replaced with the absolute copy numbers relative to the
total DNA content as measures of gene dosage, which can be
compared across tumors regardless of ploidy and normal cell
content. Hence, copy number changes that were not detected
by analysis based on ratio levels, but showed significant cor-
relation with gene expression, were found in cervical cancers,
suggesting that improved results were achieved. Moreover,
many patients with poor outcome that had MRPS23 gain by
GeneCount had no gain based on ratio levels. In the latter
case, the gain was masked by high content of normal cells or
high ploidy, showing that GeneCount is more sensitive in
detecting patients with genetic aberrations. The finding fur-
ther demonstrates that GeneCount applies well to solid
tumors for which the tumor cell fraction is generally unknown
and must be estimated by the method. Advances in current
statistical analysis methods may utilize adjustable ratio levels
for scoring gains and losses, optimizing the cut-off ratios for
each tumor based on a mathematical evaluation of the ratio
dynamics. Such methods may account for varying ploidy and
normal cell content across diploid, triploid, and tetraploid
tumors. However, the strategy is not useful for tumors with an
intermediate ploidy like 1.25 (Figure 1c). In contrast, the
absolute DNA copy number relative to the total DNA content,
or gene dosage, is comparable also across such tumors.
We also showed that GeneCount can provide genome-wide
and high resolution information of intratumor heterogeneity
in the DNA copy numbers. Such heterogeneity has previously
been detected only on a single gene basis by FISH or at low
resolution by conventional CGH analyses [14,15,20,37,38],
probably reflecting a high genomic instability [39]. Detection
of heterogeneity involving two DNA copies by the use of FISH
is challenging, since the heterogeneous tumor population is
difficult to distinguish from normal cells. The probability to
detect heterogeneity with GeneCount depends on the fraction
of tumor cells with the heterogeneous aberration. Obviously,
the probability is largest at a fraction of 50%, but fractions
higher than 70% and lower than 30% were also identified.
Heterogeneity in low copy numbers, like 1&2 and 2&3, are
more easily detected, since the separation between the log-
transformed ratio levels are larger. At higher copy numbers,
the possibility to detect heterogeneity decreases, depending
on the ploidy and normal tissue content. However, we also
identified heterogeneous regions with copy number 3&4 in
several tumors and 4&5 in one tumor. Finally, the probability
to detect heterogeneity also depends on the proportion of the
genome that is affected. In our data severe heterogeneity
affecting up to 40% of the genome could be analyzed with
GeneCount (C002/01; Additional data file 9). With an
increasingly larger part of the genome affected, difficulties in
finding breakpoints and even homogeneous aberrations
eventually occur, leading to unreliable results regardless of
analysis method.
The heterogeneity data led to insight into the evolutionary
sequence of the copy number changes. The homogeneous
aberrations had probably occurred prior to the heterogeneous
ones [14]. Moreover, in cases where the heterogeneous aber-
rations appeared to be present in different fractions of the
tumor cell population, these aberrations could be ordered
chronologically in a serial and/or parallel sequence. It was
not always possible to identify the correct sequence among
the proposed ones, as could be done by comparing data for
several biopsies from the same tumor [14]. However, identifi-
cation of the heterogeneous as well as the homogeneous aber-
rations suggests a further possible investigation of the exact
combination of aberrations in each subpopulation, employ-
ing, for example, triple-color FISH with one probe for a
homogeneous aberrant region and two for the heterogeneous
ones.
In the heterogeneity analysis we assumed that the ploidy was
the same for all subpopulations of malignant cells. This
assumption was justified because no cases were observed
with two aneuploid populations by flow cytometry. A possible
difference in the ploidy of two aneuploid populations within a
tumor was therefore probably smaller than 10%, leading to
less than 10% uncertainty in the copy numbers calculated byGenome Biology 2008, 9:R86
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tainty also applied to near diploid and heterogeneous cervical
cancers. These tumors often showed a broad G1 peak with a
CV up to 10% by flow cytometry, probably reflecting the exist-
ence of several subpopulations with ploidy within the range of
1.0-1.1. Moreover, few or no light chain positive cells were
observed in the diploid population of the aneuploid lympho-
mas, suggesting that the diploid population contained prima-
rily normal cells. It is possible, however, that the diploid
population of the aneuploid cervical cancers contained
malignant cells, as we have previously shown for aneuploid
colorectal cancers [40]. This might have led to larger uncer-
tainties in the heterogeneous copy numbers due to the use of
an erroneous DNA index of the diploid population. The data
of such tumors can be improved by sorting the diploid and
aneuploid fractions by flow cytometry [40] for separate aCGH
and GeneCount analyses.
Conclusion
GeneCount provides reliable DNA copy numbers, both when
based on the tumor cell fractions determined by flow cytome-
try and those estimated by the method. Accurate data are also
achieved in translocated chromosomal regions, as demon-
strated for the t(14;18) translocation involving BCL2. Our
method is the only one to provide genome-wide information
of absolute DNA copy numbers. Moreover, the method repre-
sents a significant improvement compared to existing meth-
ods in the study of gene dosages and intratumor copy number
heterogeneities. The robustness of GeneCount implies that
the method can be utilized widely in the genomic exploration
of both hematopoietic and solid tumors, addressing DNA
copy number aspects in a reliable manner, regardless of pos-
sible translocations. This may lead to improved assays for dis-
ease classification and outcome prediction and aid the
identification of efficient targets for new cancer therapies.
Materials and methods
Tumor samples, DNA index, and tumor cell fraction
Samples from 94 patients with B-cell non-Hodgkin's lym-
phoma and 99 patients with squamous cell carcinoma of the
uterine cervix were analyzed. We used fresh frozen lym-
phoma cell suspensions for which the tumor subtype, stage,
patient treatment, and follow-up have been presented previ-
ously [25]. The cervical cancers were of FIGO (Fédération
Internationale des Gynaecologistes et Obstetristes) stage 1b-
4b, treated with radiotherapy. Tumor biopsies taken before
the start of treatment were used.
The DI of the lymphomas and cervical cancers and the tumor
cell fraction of the lymphomas were determined by use of flow
cytometry, and most of these data have been published earlier
[14,23,25]. The lymphoma cells were labeled with phyco-
erythrin-labeled antibodies to the tumor characteristic light
chains for identifying the tumor cells and Hoechst 33258 for
assessment of DNA content. The DI was determined from the
G1 peak position of the light chain positive cells relative to the
light chain negative cells. Tumor cell fraction was determined
as the fraction of light chain positive cells. The DI of the cer-
vical cancers was assessed by preparing clean nuclei, stained
with propidium iodide, using the detergent-trypsin method
[41]. Cells from a diploid cell line were used as an internal ref-
erence. Samples showing two distinct G1 peaks in the DNA
histogram were classified as aneuploid, and the DI was deter-
mined from the position of the G1 peak of the aneuploid cells
relative to the corresponding peak of the diploid cells. Sam-
ples with a single G1 peak were classified as near diploid. An
estimate of the tumor cell fraction was achieved for each cer-
vical cancer sample by histological examination of hematoxy-
lin and eosin stained sections derived from the middle part of
the biopsies. These values were used to compare with the
tumor cell fractions estimated by GeneCount.
Array CGH
Genomic array slides produced by the Microarray Facility at
the Norwegian Radium Hospital were used [42]. The arrays
contained 4,549 unique genomic clones of BACs and P1 arti-
ficial chromosomes (PACs) (Wellcome Trust Sanger Institute,
Cambridge, UK) that covered the whole genome with a reso-
lution of approximately 1 Mb. The 1 Mb clone collection was
supplemented with tiling path probes between 1q12 and 1q25,
using overlapping BACs and PACs. The clones were from the
RPCI-11 (BAC) and the RPC1-1, -3, -4, and -5 (PAC) libraries.
Each clone was printed in 4-8 array spots. The genes covered
by the clones were found from Ensembl [43].
Genomic DNA was isolated from the lymphoma cell suspen-
sions and cervical cancer biopsies according to a standard
protocol, including proteinase K, phenol, chloroform, and
isoamylalcohol [44]. DNA (1 μg) was digested overnight,
using DpnII endonuclease (New England Biolabs, Beverly,
MA, USA), and purified using the QIAquick PCR Purification
Kit (Qiagen, Valencia, CA, USA). Digested and purified DNA
and normal reference DNA (0.5 μg each) were labeled by a
random primer reaction (BioPrime DNA Labeling System,
Invitrogen, Carlsbad, CA, USA) with Cy3-dCTP and Cy5-
dCTP (Perkin-Elmer Life Sciences, Foster City, CA, USA),
respectively, and co-hybridized to the array slides [42]. Scan-
ning and image analysis were performed by use of an Agilent
scanner (Agilent Technologies Inc., Palo Alto, CA, USA) and
the GenePix 6.0 image analysis software (Axon Instruments
Inc., Union City, CA, USA). The microarray management and
preprocessing software BASE [26] was used for spot filtering
and ratio normalization. The mean value of the 4-8 spots of
each genomic clone was used, provided that the standard
deviation was less than 0.2. Lowess normalization was per-
formed so that the mean log-transformed ratio of all clones
was equal to 0. The GLAD and CGH-Explorer algorithms
were used for ratio smoothing and breakpoint detection
[9,11]. Default values of 8 (GLAD) and 1.5 (CGH-Explorer) forGenome Biology 2008, 9:R86
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inputs to GeneCount.
Principle of GeneCount
For a heterogeneous test sample consisting of several cell
populations, like normal cells and distinct populations of
malignant cells, the DNA of each cell population contributes
to the aCGH ratio. Ideally (that is, in cases of no experimental
bias), the normalized ratio of each array probe is given by:
where Rideal is the aCGH ratio of a sample with n cell popula-
tions, and Ni, DIi, and Fi are the DNA copy number, DNA
index, and tissue fraction of cell population i, respectively. We
assume that: the reference sample is normal DNA with a copy
number of 2 throughout the genome, except for the X and Y
chromosomes in males; sex-matched hybridizations are per-
formed; and DI is given relative to the DNA content of normal
cells.
In cases of a homogeneous sample with a single cell popula-
tion, for example, a cancer cell line, Equation 1 is reduced to:
In clinical samples with two cell populations, that is, malig-
nant and normal cells, the ratio is given by:
where NT, DIT, and FT are the DNA copy number, DNA index,
and fraction of malignant cells in the sample, respectively. 1 -
FT represents the fraction of normal cells, which have a DI of
1 and DNA copy number (N) of 2.
It was clear from experiments where normal male DNA was
hybridized against female DNA that the ratio dynamics were
somewhat reduced (Figure 1e). A dynamic factor, q, was
included in Equation 3 to compensate for this effect. Since the
experimental noise was independent of the logarithm of the
ratio (Additional data file 6), Equation 3 was rewritten to
account for the reduced dynamic in the following way:
The dynamic factor represents the systematic, non-random
reduction in the log-transformed ratios caused by the experi-
mental bias and has a value between 0 and 1, where the latter
value occurs in the ideal situation without any reduction in
the ratio dynamics. The factor is a characteristic of the array
slide series and the laboratory protocol and was determined
from the ratio of the X chromosome in a control experiment
hybridizing male versus female normal DNA (Figure 1e).
Equation 4 was used in GeneCount to calculate FT and NT
from the ratio profile of the sample.
Intratumor heterogeneity in the DNA copy numbers, that is,
the cases of several populations of malignant cells in addition
to the normal cells, was identified by selecting the tumors for
which one or more of the aCGH ratio levels were different
from that corresponding to an integer value by visual inspec-
tion. The ratio distributions of the potential heterogeneous
regions were compared to the distributions of the adjacent
homogeneous aberrations by ANOVA analysis, and a P-value
of 0.05 was required to classify the aberration as heterogene-
ous. The fraction of tumor cells with a heterogeneous aberra-
tion was calculated, employing the more general Equation 1.
The DI was assumed to be the same for all subpopulations of
malignant cells.
Implementation of GeneCount in BASE
We used BASE as a platform for GeneCount and linked the
algorithm to the output of the GLAD and CGH-Explorer pack-
ages, which were implemented in our BASE version. The
method can also be developed as a separate program or inte-
grated in other aCGH analysis packages. The algorithm con-
sists of three major steps: data input for all samples;
estimation of tumor cell fraction in the cases when this
parameter is unknown; and estimation of DNA copy number
for each array probe (panel A in Additional data file 1). The
smoothed aCGH ratios served as input, together with the DI,
the q-value from control experiments with its lower and
upper limits (qmin, qmax) and, if available, the tumor cell
fraction.
In cases of unknown tumor cell fraction, this value was esti-
mated in a simulation procedure based on two selected ratio
levels, using the tumor cell fraction and DNA copy numbers
as independent and q as dependent variables. The copy num-
bers and tumor cell fraction were increased in steps of 1 and
0.01, respectively, and the corresponding q-value was calcu-
lated (panel B in Additional data file 1). To ensure high accu-
racy in the estimated fractions, it was required that the
absolute value of the selected ratio levels was larger than 0.15.
This implied that samples with a tumor cell fraction lower
than 24% in diploid and 36% in tetraploid tumors could not
be analyzed when only aberrations involving one copy
number change existed (Additional data file 12). Moreover, a
minimum absolute difference of 0.2 - that is, approximately
two times the standard deviation of the log-transformed ratio
levels (Additional data file 6) - between the two selected ratio
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estimation, only ratio levels with more than ten probes were
selected. We optimized q for each tumor by allowing the value
to vary within the limited range of qmin to qmax, typically q ±
10%, leading to fairly stable estimates of the tumor cell frac-
tion. The mean tumor cell fraction based on these estimates
and the corresponding mean q-value was used in Equation 4
to estimate the DNA copy numbers of the tumor. In cases of
known tumor cell fraction, this fraction and q from control
experiments were used in Equation 4. The source code of the
module is provided by communication to the authors. A demo
version of GeneCount in BASE is also available [45].
Fluorescence in situ hybridization
GeneCount estimates for the lymphomas were compared with
direct assessments of gene copy numbers by use of FISH. All
FISH analyses have been published previously [20-25]. Dual-
color FISH was applied to all 94 tumors. We used spectrum
orange labeled locus-specific propidium iodide DNA probes
for genes commonly aberrant in lymphomas (CCND3, BMP6,
PIM1, MYC, CDKN2A, RB1, TP53, PMAIP1, and MALT1) and
spectrum green labeled centromer probes (centromere 1, 6, 8,
17, and 18) (Vysis Inc., Downers Grove, IL, USA) for assessing
the quality of the experiment. For exploring DNA copy
number calculations in translocated chromosomal regions,
BCL2, which is frequently involved in the translocation
t(14;18)(q32;q21) in lymphomas, was considered. A dual-
color translocation probe involving BCL2 and covering the
breakpoint region was used (LSI IGH Spectrum Green/LSI
BCL2 Spectrum Orange, Vysis Inc.). Due to splitting of the
probe signal in cases of translocation, erroneous high BCL2
copy numbers were derived directly with this probe. The
BCL2 copy number was therefore corrected based on the sig-
nals from the IGH and centromere 18 probes, as described
[22].
Gene expression microarrays
Gene expressions were determined by microarray analysis of
89 of the cervical cancers and related to the GeneCount esti-
mates. We used array slides produced at the Microarray Facil-
ity at the Norwegian Radium Hospital, containing 15,000
cDNA clones. The data from 48 of the patients, with a detailed
description of the experimental procedures, have been pre-
sented [27]. Cy3- and Cy5-labeled cDNA was synthesized
from total RNA by anchored oligo(dT)-primed reverse tran-
scription and co-hybridized with a reference sample (Univer-
sal Human Reference RNA, Stratagene, La Jolla, CA, USA) to
the array slides overnight at 65°C. Scanning and image anal-
ysis were performed with an Agilent scanner and the GenePix
4.1 image analysis software, respectively. Data preprocessing,
including correction of saturated intensities, filtering of weak
and bad spots, and lowess normalization, was performed in
BASE. All hybridizations were performed twice in a dye-swap
design, and the average expression ratio based on the two
experiments was used in the further analyses.
ArrayExpress accession
The array CGH raw data have been deposited to the ArrayEx-
press repository (E-TABM-398, E-TABM-399).
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Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 is a figure showing
the calculation steps in GeneCount. Additional data file 2 is a
figure showing an example of FISH probe locations. Addi-
tional data file 3 is a figure comparing FISH DNA copy num-
bers and smoothed aCGH ratio levels in non-Hodgkin's
lymphomas. Additional data file 4 is a figure illustrating dis-
crepancies between GeneCount and FISH DNA copy num-
bers. Additional data file 5 is a figure comparing tumor cell
fractions derived by histological examination and by Gene-
Count estimation in cervical cancers. Additional data file 6 is
a figure showing the standard deviation (noise) of the log-
transformed aCGH ratios. Additional data file 7 is a figure
comparing results from ratio level and GeneCount analyses in
cervical cancers. Additional data file 8 is a table listing regions
with DNA copy number heterogeneity in non-Hodgkin's lym-
phomas. Additional data file 9 is a table listing regions with
DNA copy number heterogeneity in cervical cancers. Addi-
tional data file 10 is a figure showing tumor cell fraction
required for detection of heterogeneous copy number
changes. Additional data file 11 is a figure illustrating analysis
of the evolutionary sequence of subpopulations in heteroge-
neous tumors. Additional data file 12 is a figure showing the
minimum tumor cell fraction that can be calculated in Gene-
Count. Additional data file 13 is a figure showing the tumor
cell fraction required for detection of homogeneous copy
number changes.
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